^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CD27 expression

i
Other names: CD27, S152, TNFRSF7, Tp55
Entrez ID:
Related biomarkers:
1year
A study on the effects of Anti-GM1 on the differentiation and cytotoxic activity of NK cells in nude mice (PubMed, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi)
Conclusion NK cells can infiltrate into human renal cancer tissue and can secrete GzmB, exerting natural killing effects. Anti-GM1 can promote the maturation of NK cells but inhibit the killing activity of NK cells, which is related to its inhibition of NK cell CD107a expression and suppression of NK cell IFN-γ and GzmB secretion.
Preclinical • Journal • IO biomarker
|
IFNG (Interferon, gamma) • CD27 (CD27 Molecule) • LAMP1 (Lysosomal Associated Membrane Protein 1) • GZMB (Granzyme B) • ITGAM (Integrin, alpha M)
|
LAMP1 expression • CD27 expression
1year
Predicting biomarkers in laryngeal squamous cell carcinoma based on the cytokine-cytokine receptor interaction pathway. (PubMed, Heliyon)
A total of 7 differentially expressed genes CD27, CXCL2, CXCL9, INHBA, IL6, CXCL11, and TNFRSF17 were screened for enrichment in the CCRI signaling pathway; MR analysis showed that the CCRI receptor was a risk factor for LSCC (IVW: OR = 1.629, 95 % CI:1.060-2.504, P = 0.026); Seven differential genes were correlated with drugs, immune cells and mRNA-miNA-lncRNA, respectively; the CCRI differential gene expression analysis in the validation set was consistent with the test set results. This study provided CCRI differential gene expression by bioinformatics, and MR analysis demonstrated that cytokine receptors are risk factors for LSCC, providing new ideas for the pathogenesis and therapeutic targets of LSCC.
Journal • IO biomarker
|
IL6 (Interleukin 6) • TNFRSF17 (TNF Receptor Superfamily Member 17) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CD27 (CD27 Molecule) • CXCL11 (C-X-C Motif Chemokine Ligand 11)
|
CD27 expression
1year
Soluble PD-L1 shows no association to relapse and overall survival in early stage non-small cell lung cancer (NSCLC). (PubMed, Lung Cancer)
Although in vitro and TCGA data support the suppressive effect of sPD-L1 we were unable to translate this in our clinical setting. These results may be due to the small patient number and their heterogeneity as well as the lack of a standardized sPD-L1 ELISA. Our inconclusive results regarding the value of sPD-L1 in early stage NSCLC warrant assay validation and further investigation in larger (neo-)adjuvant trials.
Journal
|
PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • CD27 (CD27 Molecule) • ADAM10 (ADAM Metallopeptidase Domain 10)
|
CD27 expression
1year
Epstein Barr virus infection induces tissue-resident memory T cells in mucosal lymphoid tissues. (PubMed, JCI Insight)
Despite cytotoxic activity and cytokine production ex vivo, these TRMs demonstrated reduced CD27 expression and proliferation and failed to control EBV viral loads in the NALT during infection although effector memory T cells (TEMs) controlled viral titers in spleen and blood. Overall, TRMs are established in mucosal lymphoid tissues by EBV infection, but primarily systemic CD8+ T cell expansion seems to control viral loads in the context of IM-like infection.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • CD69 (CD69 Molecule) • CD27 (CD27 Molecule) • LAMP1 (Lysosomal Associated Membrane Protein 1) • GZMB (Granzyme B) • ITGAE (Integrin Subunit Alpha E) • PRDM1 (PR/SET Domain 1)
|
CD27 expression
over1year
Prognostic marker CD27 and its micro-environmental in multiple myeloma. (PubMed, BMC Cancer)
We revealed that CD27 expression levels serve as an indicative marker for the prognosis of MM patients. The CD27- PERK-ATF4 is a promising target for the treatment of MM.
Journal • IO biomarker
|
CD70 (CD70 Molecule) • CD27 (CD27 Molecule) • ATF4 (Activating Transcription Factor 4)
|
CD27 expression
almost2years
Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes (clinicaltrials.gov)
P2, N=50, Recruiting, PETHEMA Foundation | Not yet recruiting --> Recruiting | Initiation date: Mar 2024 --> Nov 2023
Enrollment open • Trial initiation date
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD19 (CD19 Molecule) • CD38 (CD38 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • CD27 (CD27 Molecule) • CD81 (CD81 Molecule)
|
CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression
|
Elrexfio (elranatamab-bcmm)
almost2years
New P2 trial
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD19 (CD19 Molecule) • CD38 (CD38 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • CD27 (CD27 Molecule) • CD81 (CD81 Molecule)
|
CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression
|
Elrexfio (elranatamab-bcmm)
almost2years
Single cell analysis revealed that two distinct, unique CD4+ T cell subsets were increased in the small intestinal intraepithelial lymphocytes of aged mice. (PubMed, Front Immunol)
They may be involved in the suppression of intestinal aging and longevity through anti-tumor immunity, elimination of senescent cells and stressed cells in the aging environment. This finding could be a breakthrough in aging research.
Preclinical • Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • CD28 (CD28 Molecule) • CD27 (CD27 Molecule)
|
IFNG expression • CD27 expression
almost2years
Combination of oligo-fractionated irradiation with nivolumab can induce immune modulation in gastric cancer. (PubMed, J Immunother Cancer)
Oligo-fractionated irradiation induces an immune-modulating effect with potential antigen spreading and the combination of radiotherapy and nivolumab may be effective in a subset of patients with gastric cancer.
Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • IL7R (Interleukin 7 Receptor) • CD27 (CD27 Molecule) • TRB (T Cell Receptor Beta Locus)
|
CD27 expression
|
Opdivo (nivolumab)
almost2years
Soluble CD27 as a predictive biomarker for intra-tumoral CD70/CD27 interaction in nasopharyngeal carcinoma. (PubMed, Cancer Sci)
Furthermore, positive expression of CD70 by NPC cells was significantly correlated with EBV infection. Our results suggest that CD70/CD27-targeted immunotherapies may be promising treatment options and that sCD27 may become an essential tool for evaluating the applicability of these therapies by predicting the intratumoral CD70/CD27 interaction in NPC.
Journal • IO biomarker
|
CD70 (CD70 Molecule) • CD27 (CD27 Molecule)
|
CD70 expression • CD27 expression
almost2years
Expansion and Polarization of Human γδT17 Cells in vitro from Peripheral Blood Mononuclear Cells. (PubMed, Bio Protoc)
• Analysis of IL-17A production post γδ T-cell expansion. This protocol is used in: Science Advances (2022), DOI: 10.1126/sciadv.abm9120.
Preclinical • Journal • IO biomarker
|
IFNG (Interferon, gamma) • CD27 (CD27 Molecule) • IL17A (Interleukin 17A) • IL7 (Interleukin 7)
|
CD27 expression
almost2years
A Comprehensive Pan-cancer Analysis of the Biological Immunomodulatory Function and Clinical Value of CD27. (PubMed, J Cancer)
DNA methylation is involved in CD27 expression in cancer. CD27, which is mutated in cancers and appears widely highly expressed and altered tumor immune invasion and stromal invasion by affecting multiple immune-related and inflammation signaling pathways, plays a significant role in CESC, HNSC, UCEC and UVM, and may be used as a therapeutic target for related cancers.
Journal • IO biomarker • Pan tumor • Immunomodulating
|
CD70 (CD70 Molecule) • CD27 (CD27 Molecule)
|
CD27 expression